仁和药业高管变动与战略调整，跨界智能硬件布局引关注

Core Viewpoint - Renhe Pharmaceutical (000650) has undergone a change in its board secretary and has responded to potential restructuring matters while diversifying into smart hardware, adjusting its fundraising projects, and facing ongoing performance pressure, necessitating attention to policy compliance dynamics [1] Group 1: Executive Changes - On February 9, 2026, the company announced that board secretary Chen Guofeng resigned for personal reasons, with Jiang Feng succeeding him. This personnel change has been completed without affecting normal operations [2] Group 2: Recent Events - In an investor interaction on February 2, 2026, the company stated that any significant restructuring plans would be announced in strict accordance with regulations, indicating that investors should pay attention to potential future disclosures [3] Group 3: Business Progress - In December 2025, the company announced its entry into the AI smart wearable sector with the launch of ULOOK AI glasses, which is expected to drive new business growth [4] Group 4: Project Developments - In December 2025, the company announced adjustments to its female health product production line, terminating the digital health product line and reallocating remaining fundraising to supplement working capital, reflecting a strategic contraction [5] Group 5: Performance Overview - For the first three quarters of 2025, the company reported a 10.07% year-on-year decline in operating revenue and an 8.79% year-on-year decline in net profit attributable to shareholders. Investors should monitor whether future annual reports show improvement [6] Group 6: Policy Regulation - On January 29, 2026, the company indicated that the new requirements of the "Special Regulations on the Registration of Traditional Chinese Medicine" have not significantly impacted the operation of traditional Chinese medicine products, but ongoing attention to regulatory implementation is necessary [7]